Inspire Medical Systems, Inc. (NYSE:INSP) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Inspire Medical Systems, Inc. has received a consensus rating of "Moderate Buy" from 14 brokerages, with an average 1-year price target of $164.50.
• The company's CFO sold 11,000 shares at an average price of $93.39, decreasing his position by 19.69%.
• Inspire Medical recently reported earnings of $0.45 EPS for the quarter, exceeding analysts' expectations and showing a 10.8% year-over-year increase in revenue.

Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $164.50.

INSP has been the subject of a number of recent analyst reports. UBS Group set a $230.00 target price on Inspire Medical Systems and gave the company a "buy" rating in a report on Tuesday, August 5th. Royal Bank Of Canada reduced their target price on Inspire Medical Systems from $215.00 to $180.00 and set an "outperform" rating for the company in a report on Tuesday, August 5th. JPMorgan Chase & Co. downgraded Inspire Medical Systems from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $195.00 to $110.00 in a report on Tuesday, August 5th. Truist Financial reissued a "hold" rating and issued a $125.00 target price (down previously from $190.00) on shares of Inspire Medical Systems in a report on Tuesday, August 5th. Finally, Lake Street Capital set a $150.00 target price on Inspire Medical Systems and gave the company a "buy" rating in a report on Tuesday, August 5th.

Insider Activity

In other news, CFO Richard Buchholz sold 11,000 shares of Inspire Medical Systems stock in a transaction on Friday, August 29th. The stock was sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the completion of the transaction, the chief financial officer owned 44,867 shares of the company's stock, valued at $4,190,129.13. The trade was a 19.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Marex Group plc acquired a new position in shares of Inspire Medical Systems during the 2nd quarter worth $541,000. Public Sector Pension Investment Board raised its stake in Inspire Medical Systems by 6.9% in the 2nd quarter. Public Sector Pension Investment Board now owns 100,505 shares of the company's stock valued at $13,043,000 after purchasing an additional 6,445 shares during the last quarter. FORA Capital LLC acquired a new position in Inspire Medical Systems in the 2nd quarter valued at about $220,000. State of Tennessee Department of Treasury raised its stake in Inspire Medical Systems by 11.3% in the 2nd quarter. State of Tennessee Department of Treasury now owns 16,445 shares of the company's stock valued at $2,134,000 after purchasing an additional 1,666 shares during the last quarter. Finally, Soleus Capital Management L.P. raised its stake in Inspire Medical Systems by 179.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 109,000 shares of the company's stock valued at $14,145,000 after purchasing an additional 70,000 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.

Inspire Medical Systems Trading Down 4.2%

Shares of INSP opened at $79.86 on Friday. The firm has a market cap of $2.36 billion, a PE ratio of 46.16, a price-to-earnings-growth ratio of 2.49 and a beta of 1.15. The company's 50 day simple moving average is $99.65 and its 200-day simple moving average is $130.99. Inspire Medical Systems has a 12-month low of $73.92 and a 12-month high of $218.52.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The company had revenue of $217.09 million during the quarter, compared to the consensus estimate of $214.50 million. During the same quarter last year, the company earned $0.32 earnings per share. Inspire Medical Systems's quarterly revenue was up 10.8% compared to the same quarter last year. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. As a group, equities research analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems declared that its board has initiated a stock repurchase program on Monday, August 11th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to reacquire up to 8.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company's leadership believes its stock is undervalued.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.